GOLETA, Calif.--(

加利福尼亚州戈尔塔--(

BUSINESS WIRE

商业热线

)--

)--

Inogen, Inc.

Inogen 公司

(Nasdaq:

（纳斯达克：

INGN

INGN

), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ, “Yuwell”), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products..

)，一家提供用于家庭护理的创新呼吸产品的医疗技术公司，今天宣布，它已与江苏裕悦医疗设备与供应有限公司（002223.SZ，“Yuwell”）达成战略合作，江苏裕悦医疗设备与供应有限公司是一家全球家庭保健医疗器械制造商，拥有全面的呼吸产品组合。。

The strategic collaboration is expected to broaden Inogen’s product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen’s innovation pipeline through R&D collaboration, and accelerate the entry of Inogen’s brand into the Chinese market.

该战略合作有望通过在美国分销某些呼吸产品和选择其他地区来扩大Inogen的产品组合，通过研发合作扩大和增强Inogen的创新渠道，并加速Inogen品牌进入中国市场。

In addition, Yuwell, through its affiliate, has agreed to invest approximately $27.2 million in Inogen, representing a 9.9% common equity interest, further cementing the collaboration and bolstering Inogen’s balance sheet..

此外，尤威尔（Yuwell）已通过其附属公司同意向Inogen投资约2720万美元，占9.9%的普通股权益，进一步巩固了合作关系，并巩固了Inogen的资产负债表。。

“The collaboration with Yuwell is a pivotal step in accelerating Inogen's growth trajectory. By expanding our product portfolio, global presence and enhancing our innovation pipeline, we expect to be well-positioned to capture new market opportunities,” said Kevin Smith, President and Chief Executive Officer.

总裁兼首席执行官凯文·史密斯（KevinSmith）表示：“与尤威尔（Yuwell）的合作是加快Inogen增长轨迹的关键一步。通过扩大我们的产品组合、全球影响力和增强我们的创新渠道，我们有望抓住新的市场机遇。”。

“This collaboration supports our commitment to delivering long-term value to our shareholders and reinforces our vision of establishing Inogen as a platform for best-in-class respiratory solutions for patients across the globe. We are confident that our collaboration with Yuwell will play a crucial role in our continued success.'.

“这种合作支持了我们为股东提供长期价值的承诺，并强化了我们的愿景，即将Inogen建立为全球患者提供一流呼吸解决方案的平台。我们相信，我们与尤威尔的合作将在我们的持续成功中发挥关键作用。”。

Alex Wu, Chairman of Yuwell, added, “Inogen is a leader in the respiratory therapy market and our strategic collaboration provides both parties with the ability to broaden their geographic reach and further meet patient needs across the world. Yuwell shares Inogen’s commitment to developing and providing innovative, quality products and we believe that together we can make a meaningful difference in the lives of respiratory patients.

Yuwell董事长Alex Wu补充道：“Inogen是呼吸治疗市场的领导者，我们的战略合作使双方能够扩大其地理范围，进一步满足世界各地的患者需求。Yuwell与Inogen一样致力于开发和提供创新的优质产品，我们相信，共同努力，我们可以为呼吸患者的生活带来有意义的改变。

Together, Yuwell and Inogen aim to define the next generation of respiratory products.”.

Yuwell和Inogen共同致力于定义下一代呼吸产品。”。

The collaboration agreement will become effective immediately, while the purchase of the equity from Inogen is expected to close during the first quarter of 2025, subject to certain customary closing conditions.

合作协议将立即生效，而从Inogen购买股权的交易预计将在2025年第一季度结束，但须遵守某些惯例交割条件。

About Inogen

关于Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions.

Inogen，Inc.（纳斯达克：INGN）是一家领先的全球医疗技术公司，提供用于家庭护理环境的创新呼吸产品。Inogen通过开发、制造和营销创新的一流呼吸治疗设备来支持患者呼吸护理，该设备用于为患有慢性呼吸系统疾病的患者提供护理。

Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease..

Inogen与患者、处方医生、家庭医疗设备供应商和分销商合作，使其呼吸治疗产品广泛可用，使患者有机会控制疾病的影响。。

For more information, please visit

有关更多信息，请访问

www.inogen.com

www.inogen.com

.

.

Inogen has used, and intends to continue to use, its Investor Relations website,

Inogen已经并打算继续使用其投资者关系网站，

http://investor.inogen.com/

http://investor.inogen.com/

, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

，作为披露重大非公开信息和遵守FD法规规定的披露义务的手段。

About Yuwell

关于Yuwell

Since its establishment in 1998, Yuwell has been at the forefront of providing cutting-edge medical device solutions to enhance patient care and improve home healthcare worldwide. Yuwell (002223.SZ) generated over US $1 billion revenue in 2023, and has a broad product portfolio across respiratory treatment, diabetes management, electronic diagnostics products, first aid solutions and rehabilitation, amongst other areas..

自1998年成立以来，Yuwell一直处于提供尖端医疗设备解决方案的前沿，以加强患者护理并改善全球家庭医疗保健。尤威尔（002223.SZ）在2023年创造了超过10亿美元的收入，在呼吸治疗、糖尿病管理、电子诊断产品、急救解决方案和康复等领域拥有广泛的产品组合。。

With a steadfast commitment to clinical excellence, Yuwell delivers high-quality, medically reliable products that empower healthcare professionals to achieve superior patient outcomes.

凭借对卓越临床的坚定承诺，Yuwell提供高质量，医学上可靠的产品，使医疗保健专业人员能够实现优异的患者结果。

With 9 state-of-the-art R&D centers and 7 advanced production facilities, Yuwell's global presence spans over 100 countries and supports more than 300,000 healthcare institutions. Yuwell touches the lives of patients around the globe by bringing professional, user-friendly medical devices into the home..

尤威尔拥有9个最先进的研发中心和7个先进的生产设施，其全球业务遍及100多个国家，支持30多万家医疗机构。尤威尔将专业、用户友好的医疗设备带到家中，触动了全球患者的生活。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements.

。本通讯中包含的所有非历史事实的陈述，包括但不限于关于Inogen未来商业计划、市场机会、财务前景、增长战略和预期经营成果的陈述，均为前瞻性陈述。

Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen’s collaboration with Yuwell; satisfaction of the closing conditions under the securities purchase agreement relating to the equity investment; the timing of closing of the equity investment; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations.

。前瞻性陈述受到许多风险和不确定性的影响，这些风险和不确定性可能导致实际结果与当前预期结果存在重大差异，包括但不限于与Inogen与Yuwell合作的潜在利益相关的风险和不确定性；满足与股权投资相关的证券购买协议项下的交割条件；股权投资的交割时间；其产品的市场接受度；竞争；其销售、营销和分销能力；其计划的销售、营销和研发活动；以及与国际业务相关的风险。

For a detailed discussion of these and other risks that could impact Inogen’s operations and financial performance, please refer to the “Risk Factors” section of its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10-Q for the calendar quarter ended March 31, 2024 and in its other filings with the Securities and Exchange Commission.

有关这些和其他可能影响Inogen运营和财务业绩的风险的详细讨论，请参阅其截至2023年12月31日的10-K表年度报告中的“风险因素”部分、截至2024年3月31日的日历季度的10-Q表季度报告以及其向证券交易委员会提交的其他文件。

These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looki.

这些前瞻性声明仅在本协议签署之日有效。Inogen不承担更新这些forward looki的任何义务。